Coverage
-
July 16, 2013
Mylan Pharmaceuticals Inc. and Sandoz Inc. on Tuesday escaped almost identical infringement suits by Teva Pharmaceuticals Ltd. after they agreed to stop using its patented technology in seeking U.S. Food and Drug Administration approval for generic versions of Teva's multiple sclerosis drug Copaxone.
2 other articles on this case.
View all »